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Purpose: Phosphatidylinositol 3-kinases/AKT pathway plays a pivotal role in he-
patocellular carcinoma (HCC). Mutant PIK3CA, encoding the p110a catalytic sub-
unit, stimulates the AKT pathway and promotes cell growth in various cancers. 
PIK3CA mutation rate has been usually reported as low frequency (<5%) in HCC 
except one report from Korea with 35.6%. Therefore, we investigated the frequency 
of PIK3CA mutations in Korean HCC patients. Materials and Methods: We se-
quenced exons1, 3, 4, 6, 7, 8, 9, 19 and 20 of PIK3CA in 268 HCC tumor tissue 
samples by Sanger method and pyrosequencing assay. Results: In this study, the 
mutations were not detected in exons3, 6, 8, and 19, and detected 1 at unknown 
SNP in exon1 and exon4, 2 at unknown SNP in exon7, 2 at unknown SNP in 
exon20. However, 1 at unknown SNP, 1 at G1635T and surprisingly all samples at 
A1634Cin exon9 were detected by Sanger method. Additional experiments with 
normal tissue, cloning experiments and a pyrosequencing assay revealed that the 
double peak at A1634C of exon9 is a pseudogene, not true mutation. The mutations 
found in this study were all different and small numbers, therefore, we cannot con-
clude specific relationship between clinical characteristics of HCC and mutation of 
PIK3CA. Conclusion: Our study suggests that the rate of PIK3CA mutation in the 
Korea population is in fact similar to the rates seen elsewhere in the world.
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INTRODUCTION
With an annual incidence of >560000 deaths, hepatocellular carcinoma (HCC) is 
globally the sixth most common malignancy and the third leading cause of cancer-
related mortality.1 Liver cancer accounts for 4% of all cancers; >70% of all liver 
cancers occur in Asia, and the incidence of liver cancer in the Far East countries, 
including Korea, China, and Japan is very high.2 Recent studies demonstrated that 
genetic alternations and signaling pathways are one of the determinants for the de-
velopment of cancer.3-5 Phosphatidylinositol 3-kinases (PI3Ks) are expressed as 
heterodimers of p110 catalytic subunits, and p85 regulatory subunits interact with 
phosphatidylinositol-3-phosphate at the membrane and catalyze the phosphoryla-
tion of AKT, which activates the downstream signaling pathway.6 PI3K/AKT/
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p110a catalytic subunit] stimulates the AKT pathway and 
promotes cell growth in various types of cancer,9 including 
breast, colon, brain, gastric and lung.10-12 Moreover, over 
75% of mutations occur in the helical and kinase domains 
and these locations are likely to function as an oncogene in 
human cancer.7 The mutation of PIK3CA in HCC has been 
investigated, where most reports cited low frequency of mu-
tation (0-3.5%) except for a Korean report (35.6%),13 0% 
(0/47) in Japan,14 3.5% (2/57) in France,15 2% (1/50) in 
Switzerland,16 1.1% (1/90) in China17 and 28% (18/65) in 
South Italy.18 Therefore, we investigated whether the muta-
tion of PIK3CA varies depending on races or regions, em-




A total of 268 consecutive patients who had undergone sur-
gery for HCC at Samsung Medical Center from July 2000 
and May 2006 were included in this study. All cases were 
histopathologically confirmed after operation. This study 
was performed with appropriate Institutional Review Board 
approval. The clinical characteristics of the subjects are 
shown in Table 1. Genomic DNA was extracted from tu-
mors and normal tissues obtained from fresh frozen tissue 
using QIAamp DNA Mini Kit® (Qiagen, Hilden, Germany).
Polymerase chain reaction (PCR)
We designed polymerase chain reaction (PCR) primers us-
ing the Primer 3 program. Primer pairs were designed to 
produce about 500 base pairs by PCR, and their TMs ranged 
between 59°C and 62°C. PCR was performed with 20 ng of 
genomic DNA as the template in a 30 µL reaction mixture 
by using a EF-Taq (SolGent, Daejeon, Korea) as follows: 
activation of Taq polymerase at 95°C for 2 minutes, 35 cy-
cles of 95°C for 1 minute, 55°C, and 72°C for 1 minute each 
were performed, finishing with a 10-minute step at 72°C. 
Cloning & DNA sequencing
The amplification products were purified with a multiscreen 
filter plate (Millipore Corp., Bedford, MA, USA). Frag-
ments were ligated into a pTOP TA vector using a MGTM 
TOPcloner TA kit (Enzynomics, Daejeon, Korea). Se-
quencing reaction was performed using a PRISM BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA). The DNA samples containing 
mTOR pathway plays a pivotal role in HCC and is activated 
in 30-50% of HCC cases.7,8 Mutant phosphoinositide-3-ki-
nase [catalytic alpha polypeptide (PIK3CA), encoding the 
Table 1. Clinical Characteristics of Patients
Age, median (range) 53 (17-76)
Sex F: 50, M: 218 (18.7 : 81.3)
Etiology
    Alcohol   14 (5.2%)
    HBV 198 (79.9%)
    HBV/HCV     7 (2.6%)
    HCV   27 (140.1%)
    Biliary     2 (0.7%)
    Unknown   20 (7.5%)
Smoking
    Yes 146 (54.5%)
    No 122 (45.5%)
Alcohol
    Yes 167 (62.3%)
    No 101 (37.7%)
Child Pugh classification
    A  257 (95.9%)
    B     7 (2.6%)
    C     4 (1.5%)
Size, median (range) 3.7 cm (1.1-21.0)
    Size <5 cm 171 (63.8%)
    Size ≥5 cm   97 (36.2%)
Vascular invasion
     Yes 141 (52.6%)
     No 127 (47.4%)
Major portal vein invasion 
     Yes   12 (4.5%)
     No 256 (95.5%)
Intrahepatic metastasis
     Yes   61 (22.8%)
     No 207 (77.2%)
AJCC stage
     1 116 (43.3%)
     2 105 (39.2%)
     3a   30 (11.2%)
     3b   11 (4.1%)
     4     6 (2.2%)
AFP (ng/mL)
    <400 182 (67.9%)
    ≥400   76 (28.4%)
Recurrence
    0 (none)   88 (32.8%)
    1 (recur) 167 (62.3%)
Death
    0 (alive) 149 (55.6%)
    1 (dead) 114 (42.5%)
    2 (dead by non-hepatic cause)     5 (1.9%)
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exon4, 2 of 265 at unknown SNP (C1306A) and 1 of 265 at 
unknown SNP (C1373A) in exon7, 1 of 262 at unknown 
SNP (T2970A) and SNP (G3026A) in exon20 (Fig. 1A). 
However, in exon9 we detected 1 of 266 at unknown SNP 
(C1629T), 1 of 268 at G1635T (E545D) and surprisingly we 
observed a nucleotide alteration in 266 of 266 at A1634C 
(E545A) (Fig. 1B).
We investigated whether two peaks at nucleotide position 
1634 in exon9 was a true mutation or not. However, PCR 
products from 52 normal tissues also had all nucleotides 
changed in exon9. For the exact detection, PCR amplifica-
tion and subsequent cloning with 5-7 colonies picked both 
forward and reverse direction in 50 HCC tumor samples and 
10 colonies picked forward direction in 34 matched normal 
tissue samples. Furthermore, sequencing of the PCR prod-
ucts revealed A1634C mutation in all samples in each 5-10 
clone from the same sample (supplementary data). Howev-
er, we need to confirm whether the nucleotide change 1634 
A→C was real because chromosome 22 has C at 1634 and 
C at 1658 sequencing. In order to confirm pseudogene re-
sults and sequencing methods, we performed pyrosequenc-
ing assay with HCC tumor tissues, and found that all 268 
samples showed A at nucleotide 1634 (Fig. 2). Additional 
experiments with normal tissue, cloning experiments and 
pyrosequencing assay revealed that codon 545 of exon9 was 
all wild type. With these results, we analyzed the sequence 
of PIK3CA. Since the mutations found in our study were all 
different and so small numbers, we cannot conclude any 
specific relationship between mutation in the exon of PIK-
3CA and clinical characteristics of HCC (Table 2).
the extension products were added to Hi-Di formamide 
(Applied Biosystems, Foster City, CA, USA). The mixture 
was incubated at 95°C for 5 min, followed by 5 min on ice 
and then analyzed by ABI Prism 3730XL DNA analyzer 
(Applied Biosystems, Foster City, CA, USA). 
Pyrosequencing
Mutation analysis was performed by pyrosequencing on the 
PyroMark Q24 (Qiagen, Germantown, MD, USA). First, 
PCR products were immobilized on streptavidin-coated 
beads and denatured to produce single-stranded products. 
Pyrosequencing was performed using the PyroMark Gold 
Q24 reagent (Qiagen, Germantown, MD, USA), according 
to the manufacture’s protocol. Exon9 primers for the for-
ward: 5’(Biotin)-ATTTCTACACGAGATCCTCTCTCT-3’. 
Reverse primer: 5’-CCATTTTAGCACTTACCTGTGAC-3’ 
sequencing primer: 5’-TAGAAAATCTTTCTCCTG-3’. 
Sequencing analysis was performed using PyroMark Q24 





To investigate the frequency of PIK3CA mutations in Kore-
an patients with HCC, we sequenced the exon1, 3, 4, 6, 7, 8, 
9, 19 and 20 of PIK3CA in 268 HCC samples. In these ex-
periments, mutations were not detected in exon3, 6, 8, or 19 
in any of the HCC samples and detected 1 of 268 at unknown 
SNP (G278A) in exon1 and at unknown SNP (C848G) in 
Fig. 1. Sequencing results of PIK3CA gene. (A) Electropherograms show the SNP in each exon in 268 HCC samples. (B) Electropherograms show the nucleo-
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tected in exons 3, 6, 8, and, 19 and detected 1 of 268 at 278 
G→A in exon1 and at 848 C→G in exon4, 2 of 265 at 1306 
C→A and 1 of 265 at 1373 C→A in exon7, each of 262 at 
2970 T→A and 3026 G→A in exon20. However, 1 of 266 
was detected at 1629 C→T, 1 of 268 at 1635 G→T and 266 
of 266 at 1634 A→C in exon9. For validation with normal 
matched tissues, we found that 1634 A→C also occurred. 
Through cloning and pyrosequencing methods, the dou-
ble peak at A1634C of exon9 was found not to be a muta-
tion, but occurred as a result of gene duplication on 22q11 
partial region. Cat Eye Syndrome is a hereditary disease 
characterized by ocular colobomata, anal atresia, congenital 
heart defects, and mental retardation, and mutations are lo-
cated on human chromosome 22q11.19 We confirmed that 
the nucleotide sequence of exon9 has a highly homologous 
match rate (97%) on chromosome 22 in NCBI BLAST as 
Tanaka, et al.14 previously mentioned. A1634C was found 
in all samples. For more exact analysis, we analyzed 10 
colony sequencing per each sample through cloning experi-
ments, and found 1633-GAGCAGGAGAAAGATTTTC 
TATGGAGTCACAG in PIK3CA and 1633-GCGCAG 
GAGAAAGATTTTCTATGGACCACAG in chromosome 
22. Yet, when the sequence occurred from C or G at posi-
tion 1634 to GT at position 1658, this was a mutation. How-
ever, there might be different results as wild type and pseu-
dogene mutation depending on clones in one sample; if 
there is a mutation in one clone even within the same sam-
DISCUSSION
PIK3CA has been shown to be mutated in various tumors 
and recognized as a possible therapeutic marker. More than 
70% of all liver cancers occur in Asia, while the frequency of 
mutation varied among several reports from Asia. If PIK3CA 
mutation of HCC in Korean patients is specifically higher as 
reported by Lee, et al.13 who investigated 73 HCC tissues, it 
might be a new target of Korean HCC. For this reason, con-
firmatory study is needed, including more tissues. 
We sequenced exons1, 3, 4, 6, 7, 8, 9, 19 and 20 of PIK-
3CA in 268 HCC tumor tissues. The mutations were not de-
Table 2. Relationship between Mutation in the Exon of PIK3CA and Clinical Characteristics
RefSNP
Exon 1 Exon 4 Exon 7 Exon 9 Exon 20
Unknown Unknown Unknown Unknown Unknown rs121913275 Unknown Unknown 
Position G278A C848G C1306A
C1373A, 
C1306A
C1629T G1635T T2970A G3026A
Sample ID 35 441 67 5 355 507 255 63
Age 66 58 58 53 66 44 71 43
Sex M M M M M M M M
Etiology B BC B B C B Alcohol B
Alcohol No Yes Yes Yes Yes Yes Yes No
Child-Pugh 
  classification
A A A A A A A A
Size (mm) 64 85 20 100 32 25 100 123
Vascular invasion No Yes No Yes No Yes Yes Yes
Main portal 
  vein invasion
No Yes No No No No No No
Intrahepatic 
  metastasis
No Yes No Yes No No Yes No
BCLC stage B C A1 B A1 A1 B B




Recurrence No Yes No Yes No Yes No Yes
Fig. 2. Results of codon 545 by pyrosequencing. Pyrosequencing results 
show the specificity of PIK3CA amplification for codon 545. Pyrogram for 
amplification of a sample using PIK3CA condon 545 is GAG, and the pseu-
dogene was not amplified.
Gene reverse synthesis
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ple, it will be considered to be a mutation. As the number of 
clones increase, the probability of mutations in all samples 
will be increasing. 
This analysis was not optimal because primers are likely 
to amplify both genes, PIK3CA exon9 and chromosome22. 
For analysis of nucleotide 1634, pyrosequencing is more 
efficient at the amplification step in heterogeneous samples. 
Detection of codon 545 of PIK3CA is well suited to be ex-
amined by pyrosequencing as Baker, et al.20 mentioned re-
cently. Following Baker, et al.’s methods, we confirmed again 
that all samples were wild type at codon 545.
In this study, unknown SNP G278A, C848G, C1306A, 
C1373A, C1629T, T2970A, G3026A were found, however, 
only 8 cases of 268 HCC tumor tissues were found to be 
mutated. Even though we found low mutation frequency in 
our samples, amplification or mutation of PIK3CA has 
been reported in various cancer types, and the question of 
whether PIK3-AKT pathway is activated in HCC remains 
still controversial. Nevertheless, it is highly possible that 
this gene is a promising molecular target for cancer treat-
ment. As nucleotide1634 in exon9 has sequence very simi-
lar to chromosome22, pyrosequencing assay for excluding 
pseudogene interference appears to be more proper for de-
tecting mutation. 
In conclusion, our study suggests that the rate of PIK3CA 
mutation in the Korea population is in fact similar to the 
rates seen elsewhere in the world.
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